A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis

Prior treatment

• Participants who have developed an AE while participating in the Parent Study which, in the opinion of the Investigator or of the Medical Monitor, could indicate that continued treatment with APG777 may present an unreasonable risk for the patient
• Participants who terminated early from the Parent Study or permanently discontinued the study drug during the Parent Study
• Use of any of the prohibited medications from Screening Visit (Visit 1) of the LTE study

Other illness

• Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or interfere with study assessments

• Participants who have completed the Treatment Period in a prior APG777 study and were, in the Investigator’s opinion, compliant with the study protocol
• Participants who, in the Investigator’s opinion, would benefit from long-term treatment with APG777
• Use the same non-prescription non-medicated emollient/moisturizer of their choice from the last day of the Parent Study and throughout the LTE study